Patents Examined by Sagar Patel
  • Patent number: 10487093
    Abstract: This invention relates to antibacterial drug compounds containing a bicyclic core, typically a bicycle in which one of the rings is an oxazolidinone. It also relates to pharmaceutical formulations of antibacterial drug compounds. It also relates to uses of the compounds in treating bacterial infections and in methods of treating bacterial infections.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: November 26, 2019
    Assignee: Redx Pharma PLC
    Inventors: Ian Cooper, Amanda Lyons, David Orr, James Kirkham, Kevin Blades
  • Patent number: 10478421
    Abstract: Provided herein are compounds and formulations thereof that can be capable of binding to sortilin or an analogue thereof. Also provided herein are methods of administering the compounds and formulation provided herein to a subject in need thereof.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: November 19, 2019
    Assignees: University of Florida, University of Rochester
    Inventors: Robert Pleasants Sparks, Wayne Charles Guida, Janet Lindsay DeHoff-Sparks
  • Patent number: 10464940
    Abstract: Compounds useful as kinase inhibitors are provided herein, as well as salts, pharmaceutical compositions, methods of medical treatment and methods of synthesis thereof.
    Type: Grant
    Filed: January 2, 2018
    Date of Patent: November 5, 2019
    Assignee: GI Therapeutics, Inc.
    Inventor: Francis Xavier Tavares
  • Patent number: 10464885
    Abstract: The present invention relates to a compound and its preparation method and use and corresponding targeted drug delivery systems and chemotherapeutic drugs. The compound is a novel compound or a pharmaceutically acceptable salt thereof for treating small cell lung cancer, characterized in that, the compound has the general formula I, wherein R is acyloxy group. The present invention also relates to a preparation method of the compound, to use of the compound for the preparation of a chemotherapeutic drug for treating small cell lung cancer, to a targeted drug delivery system including the compound, and to a chemotherapeutic drug including the compound and for treating small cell lung cancer.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: November 5, 2019
    Inventors: Xuechun Lu, Xiaohua Chi, Chengcheng Tang, Lei Shi
  • Patent number: 10463672
    Abstract: Salts and solid forms of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a stereoisomer thereof, are disclosed. Compositions comprising and methods of using the salts and solid forms are also disclosed.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: November 5, 2019
    Assignee: Celgene Corporation
    Inventors: Benjamin M. Cohen, John F. Traverse, Jean Xu, Ying Li
  • Patent number: 10456379
    Abstract: The present invention relates to novel therapeutic agents suitable for use in the treatment of mammalian disease and in particular to novel therapeutic agents suitable for use in the treatment of microbial infection in mammals. The present invention further relates to the use of pharmaceutical compositions comprising said agents in the treatment of medical conditions in mammals, in particular in the treatment of microbial infection. The agents and pharmaceutical compositions of the invention are of particular relevance in the treatment of diseases associated with antibiotic-resistant microbes.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: October 29, 2019
    Assignee: Procomcure Biotech GmbH
    Inventors: Kamil Önder, Roelf Datema
  • Patent number: 10450301
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: October 22, 2019
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Brett Granger, Guoqiang Wang, Ruichao Shen, Jing He, Yong He, Xuechao Xing, Jun Ma, Jiang Long, Bin Wang, Yat Sun Or
  • Patent number: 10435369
    Abstract: There are described ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: October 8, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: David Marcoux, Myra Beaudoin Bertrand, T. G. Murali Dhar, Michael G. Yang, Zili Xiao, Hai-Yun Xiao, Yeheng Zhu, Carolyn A. Weigelt, Douglas G. Batt
  • Patent number: 10428030
    Abstract: The present application relates to novel heterocycle derivatives of Formula (I), to processes for preparing them, pharmaceutical compositions containing them, and their use thereof in the treatment or prevention of acute and/or chronic neurological disorders such as psychosis, epilepsy, schizophrenia, Alzheimer' disease, cognitive disorders and/or memory deficits, as well as chronic and acute pain and other related CNS disorders.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: October 1, 2019
    Assignee: Trillium Therapeutics
    Inventor: Abdelmalik Slassi
  • Patent number: 10421716
    Abstract: The invention relates to a novel process for preparing ?-carboxamide pyrrolidine derivatives, in particular (2S, 5R)-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxamide, and to novel intermediates for use in said process along with processes for preparing said intermediates.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: September 24, 2019
    Assignee: Convergence Pharmaceuticals Limited
    Inventors: David MacPherson, David Witty, Gerard Giblin, Michael Williams, Donald Walker, William Kiesman, Tamera Mack
  • Patent number: 10406167
    Abstract: The present disclosure relates platinum(IV) and texaphyrin linked conjugates and compositions comprising a texaphyrin and a platinum(IV) agent. The present disclosure also provides pharmaceutical compositions of the conjugates and compositions. Also, provided herein are methods of using the instant compounds in the treatment of cancer such as a platinum resistant cancer.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: September 10, 2019
    Inventors: Jonathan L. Sessler, Jonathan Arambula, Zahid H. Siddik, Gregory Thiabaud
  • Patent number: 10399972
    Abstract: The present invention is directed to tricyclic compounds of formula (I), (Ia) or (Ib) which are inhibitors of one or more mutant IDH enzymes. The present invention is also directed to uses of these tricyclic compounds in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: September 3, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: David J. Witter, Tesfaye Biftu, Purakkattle Biju, Stephane L. Bogen, Qingmei Hong, Chunhui Huang, Xianhai Huang, Bing Li, Min K. Park, David L. Sloman
  • Patent number: 10392351
    Abstract: Disclosed in the present invention is a method for preparing nilotinib intermediate 3-(4-methyl-1H-imidazol-1-yl)-5trifluoromethyl phenylamine (I). The method comprises the following steps: taking trifluorotoluene as an initial material, and preparing the nilotinib intermediate (I) by nitration, bromization, condensation and reduction successively Compared with the prior art, the preparation method has the following advantages: a relatively high yield, the raw materials are easily obtained, a concise process and few side reactions, and is adapted to industrial production, so the development of an economic technology of the bulk drug is promoted.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: August 27, 2019
    Inventors: Xuenong Xu, Deli Zeng, Liang Shu, Qing Zhang, Zhijian Bao, Jia Xue, Jian Su, Zhe Wang, Wenjie Zhou, Lingling Xie
  • Patent number: 10391182
    Abstract: Cytotoxic dimers comprising CBI-based and/or CPI-based sub-units, antibody drug conjugates comprising such dimers, and to methods for using the same to treat cancer and other conditions.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: August 27, 2019
    Assignee: Pfizer Inc.
    Inventors: Andreas Maderna, Matthew David Doroski, Zecheng Chen, Hud Lawrence Risley, Jeffrey Michael Casavant, Christopher John O'Donnell, Alexander M. Porte, Chakrapani Subramanyam
  • Patent number: 10369150
    Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is a divalent linking moiety; and R1-R10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R3 or R8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: August 6, 2019
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, The United States of America as represented by the Department of Veterans Affairs
    Inventors: Beibei Chen, Rama K. Mallampalli
  • Patent number: 10364220
    Abstract: The present invention relates to the synthesis of succinimides, in particular to a method for the synthesis of a succinimide compound, comprising the step of reacting an alkyne, with carbon monoxide and ammonia or an amine, in the presence of an iron catalyst, wherein the reaction is carried out in an amine liquid phase and/or in the absence of an ether solvent. The succinimides may be reduced to quaternary ammonium cations which may be used as structure directing agents in the synthesis of molecular sieves.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: July 30, 2019
    Assignee: ExxonMobil Chemical Patents Inc.
    Inventors: Kirk D. Schmitt, Stephen Zushma, Allen W. Burton
  • Patent number: 10328027
    Abstract: A new scalable process to control the particle size and the particle size distribution, comprising 5 steps: (i) suspension preparation in a mixture of solvents in which the API and/or excipient is partially soluble in one of the solvents; (ii) particle size reduction of the suspension; (iii) aging; (iv) stopping the aging by solvent removal; and (v) optionally, a step of isolating the processed ingredients in the form of powder.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: June 25, 2019
    Assignee: Hovione International Ltd.
    Inventors: Eunice Costa, Marcio Temtem, Luis Sobral, Constanca Cacela, Peter Villax
  • Patent number: 10323030
    Abstract: Compounds of formula (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides and can be prepared in a manner known per se.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: June 18, 2019
    Assignee: Syngenta Participations AG
    Inventors: Ottmar Franz Hueter, Andrew Edmunds, Andre Jeanguenat, Pierre Joseph Marcel Jung, Anke Buchholz, Michel Muehlebach
  • Patent number: 10308606
    Abstract: The present disclosure relates to prostate specific membrane antigen (PSMA) targeted compounds conjugated to near-infra red (NIR) dyes and methods for a method for synthesizing a compound of the formula:
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: June 4, 2019
    Assignee: On Target Laboratories, LLC
    Inventors: Sumith A. Kularatne, Pravin Gagare
  • Patent number: 10301323
    Abstract: This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3).
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: May 28, 2019
    Inventors: Vincent Jacques, James R. Rusche, Norton P. Peet, Jasbir Singh